Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome.

@article{Matzkies1999EfficiencyO1,
  title={Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome.},
  author={Fritz K. Matzkies and Udo Bahner and Markus Teschner and Helge Hohage and August Heidland and Roland Michael Schaefer},
  journal={American journal of nephrology},
  year={1999},
  volume={19 4},
  pages={492-4}
}
The influence of fluvastatin, a liver-selective, competitive inhibitor of the 3-hydroxymethyl-glutaryl-coenzyme A reductase, on the lipoprotein metabolism was investigated in 9 patients with nephrotic syndrome. All patients had biopsy-proven renal disease as cause of their nephrotic syndrome and exhibited severe hyperlipidemia [baseline: serum cholesterol 358 +/- 46 mg/dl (9.3 mmol/l), low-density lipoprotein cholesterol 236 +/- 18 mg/dl (6.1 mmol/l), triglycerides 333 +/- 28 mg/dl (3.8 mmol/l… CONTINUE READING